The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

The companies, which have at times had an adversarial relationship, also said they would develop a roadmap to continue their ...

A federal judge in Texas handed Novo Nordisk (NVO) a big win late Thursday in its battle against cheaper versions of its ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

Gavin Newsom’s administration has reported that half of the doubling in Medi-Cal costs over the past six years has been from ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

For example, many patients have relied on compounding pharmacies for access to wildly popular diabetes and weight loss drugs, ...

“Within the Medi-Cal program, semaglutide has comprised most of the utilization of GLP-1 agonists, mostly for Ozempic.” Because benefits for illegal immigrants are not eligible for state funding or ...

What if you could lose weight with a daily pill instead of painful weekly jabs like you would with Ozempic, the injectable ...